Anzahl der Publikationen: 10
2022
Braulke, Friederike; Zettl, Florian; Ziepert, Marita; Viardot, Andreas; Kahl, Christoph; Prange-Krex, Gabriele; Korfel, Agnieszka; Dreyling, Martin; Bott, Alexander; Wedding, Ulrich; Reichert, Dietmar; de Wit, Maike; Hartmann, Frank; Poeschel, Viola; Schmitz, Norbert; Witzens-Harig, Mathias; Klapper, Wolfram; Rosenwald, Andreas; Wulf, Gerald; Altmann, Bettina und Trumper, Lorenz
(2022):
First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial.
In: Hemasphere, Bd. 6, Nr. 12, e808
Hess, Georg; Huettmann, Andreas; Witzens-Harig, Mathias; Dreyling, Martin H.; Keller, Ulrich; Marks, Reinhard; Ernst, Thomas; Pott, Christiane; Viardot, Andreas; Frontzek, Fabian; Trautmann, Marcel; Ruckes, Christian; Deuster, Oliver; Rosenwald, Andreas; Theobald, Matthias und Lenz, Georg
(2022):
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.
In: British Journal of Haematology, Bd. 198, Nr. 3: S. 482-491
2021
Witzens-Harig, Mathias; Viardot, Andreas; Keller, Ulrich; Wosniok, Julia; Deuster, Oliver; Klemmer, Jennifer; Geueke, Anne-Marie; Meissner, Julia; Ho, Anthony D.; Atta, Johannes; Marks, Reinhard; La Rosee, Paul; Buske, Christian; Dreyling, Martin H. und Hess, Georg
(2021):
The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM Trial.
In: Hemasphere, Bd. 5, Nr. 10, e636
2020
Hess, Georg; Wagner, Karola; Keller, Ulrich; La Rosee, Paul; Atta, Johannes; Hübel, Kai; Lerchenmueller, Christian; Schoendube, Daniel; Witzens-Harig, Mathias; Ruckes, Christian; Medler, Christoph; Oordt, Christina van; Klapper, Wolfram; Theobald, Matthias und Dreyling, Martin
(2020):
Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma.
In: Hemasphere, Bd. 4, Nr. 3, e398
2019
König, Laila; Dreyling, Martin; Duerig, Jan; Engelhard, Marianne; Hohloch, Karin; Viardot, Andreas; Witzens-Harig, Mathias; Kieser, Meinhard; Klapper, Wolfram; Pott, Christiane und Herfarth, Klaus
(2019):
Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro)-GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial.
In: Trials, Bd. 20, Nr. 1, 544
2018
2017
Hess, Georg; Rule, Simon; Jurczak, Wojciech; Jerkeman, Mats; Silva, Rodrigo Santucci; Rusconi, Chiara; Caballero, Dolores; Joao, Cristina; Witzens-Harig, Mathias; Bence-Bruckler, Isabelle; Cho, Seok-Goo; Zhou, Wenjiong; Goldberg, Jenna D.; Trambitas, Cristina; Enny, Christopher; Vermeulen, Jessica; Traina, Shana; Chiou, Chiun-Fang; Diels, Joris und Dreyling, Martin
(2017):
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.
In: Leukemia & Lymphoma, Bd. 58, Nr. 12: S. 2824-2832
2016
Dreyling, Martin; Jurczak, Wojciech; Jerkeman, Mats; Santucci Silva, Rodrigo; Rusconi, Chiara; Trneny, Marek; Offner, Fritz; Caballero, Dolores; Joao, Cristina; Witzens-Harig, Mathias; Hess, Georg; Bence-Bruckler, Isabelle; Cho, Seok-Goo; Bothos, John; Goldberg, Jenna D.; Enny, Christopher; Traina, Shana; Balasubramanian, Sriram; Bandyopadhyay, Nibedita; Sun, Steven; Vermeulen, Jessica; Rizo, Aleksandra und Rule, Simon
(2016):
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study.
In: Lancet, Bd. 387, Nr. 10020: S. 770-778
2013
2011
Diese Liste wurde am
Sat Aug 10 22:29:48 2024 CEST
erstellt.